Browse all practice questions for the BPS Sterile Compounding Practice Exam. Search by topic, open any question and review its full explanation, then test yourself in the practice quiz.

BPS Sterile Compounding Practice Exam 2026 – Complete Test Prep course image
All questions

These questions are part of the practice quiz. Start practicing

  • Which temperature is considered acceptable for storing low-risk CSPs when frozen?
  • What must be true about filters used for sterilizing CSP solutions?
  • How often should environmental sampling be performed according to best practices?
  • What is a common bacteriostatic agent used in compounding?
  • What is a compounding record?
  • What is a key difference between a Segregated Compounding Area (SCA) and a Buffer Room?
  • What document outlines the sterile compounding policies in a pharmacy?
  • What does the right documentation in medication administration ensure?
  • What is the preferred temperature range for storing compounded sterile preparations?
  • What procedures are essential for verifying the accuracy of a compounded sterile preparation?
  • Which method is used for sterilization in a Segregated Compounding Area (SCA)?
  • Where must hazardous drugs (HDs) be stored according to USP 797?
  • When is a Master Formulation Record (MFR) necessary?
  • If contamination is suspected during compounding, what steps should be taken?
  • Non-viable airborne particle testing directly measures what aspect?
  • What is the recommended integrity test for sterilization filters?
  • How often must media fill testing be conducted for high risk compounded sterile preparations?
  • What is the purpose of a validation process in sterile compounding?
  • What is the maximum storage period for high risk CSPs at controlled room temperature in the absence of sterility tests?
  • Which USP chapter is associated with sterilization and sterility assurance of compendial articles?
  • What is the preferred method for terminally sterilizing aqueous CSPs?
  • What is the minimum air change per hour (ACPH) required in a buffer area?
  • Why is regular equipment maintenance important in sterile compounding?
  • What is the pressure setting when using an autoclave for steam sterilization?
  • Which type of risk level is associated with sterilization by filtration?
  • What is the volume range for a small volume parenteral?
  • For low and medium risk CSPs, what is the recommended frequency of Active (Viable) Air Sampling?
  • Why is training pharmacy staff on sterile compounding techniques important?
  • What is an essential element of effective environmental monitoring in a compounding area?
  • What is the main consequence of failing to verify drug compatibility during compounding?
  • What volume defines a large volume parenteral?
  • In which situations is it appropriate to use compounded sterile preparations?
  • What is the primary purpose of performing media fill tests?
  • What should be done if a compounded sterile preparation fails sterility testing?
  • What is the recommended duration of treatment for central line parenteral nutrition (PN) due to potential complications?
  • What materials are preferred for constructing the walls of a buffer room in sterile compounding practice?
  • What should be included in the training documentation for sterile compounding personnel?
  • What is the maximum allowable humidity in a Sterile Product Complex?
  • Which type of injection is included in the restriction against using bacteriostatic diluents?
  • What does "first air" refer to in laminar airflow hoods?
  • What is the consequence of using non-sterile water in the preparation of high risk CSPs?
  • What is the osmolality threshold for a drug administered via a central line?
  • What should be done for allergen extracts prior to compounding?
  • For how long can refrigerated medium risk CSPs be stored in the absence of sterility tests?
  • What is the highest priority when considering critical sites in sterile compounding?
  • What must be done in a segregated compounding area (SCA) for low-risk CSPs?
  • What are the advantages of using automated compounding devices?
  • What type of growth medium is used for surface sampling in Active (Viable) Air Sampling?
  • How can compounding accuracy be verified?
  • How long should items be sterilized using dry heat at 160 degrees C?
  • What does the term "sterility assurance level" (SAL) refer to?
  • Which populations are specifically contraindicated for the use of bacteriostatic diluents?
  • What is the purpose of maintaining a cleanroom log book?
  • Which of these methods is suitable for sterilization in a Compounding Environment?
  • What is the definition of a "compounding pharmacy"?
  • What is the recommended action level for CFU in ISO 5 air sampling?
  • Which ISO class is typically required for areas where sterile compounding occurs?
  • What is indicated by visible turbidity in the medium during a media fill test?
  • What is the objective of determining the sterility assurance level (SAL)?
  • At what temperature is depyrogenation achieved using dry heat?
  • What do the terms "beyond-use date" and "expiration date" signify?
  • For low-risk CSPs, what type of PECs are permitted?
  • Which of the following methods could potentially reduce CFU counts?
  • What is the maximum number of sterile products that can be pooled together for medium risk CSPs?
  • Which components are essential on a sterile product label?
  • What does USP 800 focus on in healthcare settings?
  • What is the function of benzyl alcohol in some sterile compounded preparations?
  • What relative humidity should be maintained within a C-SCA?
  • Why is double-checking calculations critical during compounding?
  • When performing manipulations of low-risk CSPs, what is permitted?
  • Which of the following is a requirement for the immediate use provision?
  • Which method is NOT typically used for achieving sterility in high risk CSPs?
  • What is the recommended growth medium for Active (Viable) Air Sampling to promote bacteria growth?
  • Which factors must be taken into account when determining the stability of a compounded sterile preparation?
  • What is the primary risk associated with hyperosmolality in PN treatment?
  • Which of the following is NOT a bacteriostatic agent?
  • What pressure differential should exist between the ISO 7 buffer room and the ante room?
  • What is the significance of the sterile compounding policy and procedure manual?
  • What distinguishes terminal sterilization from aseptic processing?
  • What does an MFR stand for in sterile compounding?
  • What is the recommended incubation period for media fill tests at both low and medium risk levels?
  • Which type of risk level is allowed under the immediate use provision?
  • What is the main purpose of USP 797?
  • What are the characteristics of the furniture used in the buffer room?
  • How long should TSA be incubated for Active (Viable) Air Sampling?
  • What are the allowed total particle counts for ISO 5 classification?
  • Why is proper hand hygiene critical in sterile compounding?
  • Which of the following is NOT a requirement for low-risk level CSPs?
  • What materials are suitable for work surfaces in a buffer room?
  • Which type of flooring is recommended for a buffer room in sterile compounding?
  • Which of the following best describes the responsibility of compounding personnel?
  • How should epidermal compounded sterile products be treated with respect to bacteriostatic agents?
  • Which of the following describes Secondary Engineering Controls (SECs)?
  • Which chapter of USP deals primarily with radiopharmaceuticals?
  • What element should NOT be included on a sterile product label?
  • Why is terminal filtration by membrane filtration preferred over direct inoculation?
  • What should be done with compounded sterile preparations that have exceeded their beyond-use date?
  • What is a characteristic of an environment suitable for the preparation of medium risk compounded sterile preparations (CSPs)?
  • What is the longest allowed storage time for high risk CSPs when frozen?
  • What distinguishes non-hazardous sterile compounding from hazardous sterile compounding?
  • Which of the following tests can confirm the sterility of a compounded preparation?
  • What type of equipment can be used for a low-risk level CSP?
  • Terminal filtration is primarily used for what purpose in compounding sterile products?
  • Which method of sterility testing is favored to extend beyond-use dates (BUD)?
  • What facilities are designated for CAIs in terms of ISO classification?
  • What document must accompany compounded sterile preparations when dispensed to patients?
  • What is the beyond-use date (BUD) for opened or needle-punctured single-dose containers in ISO 5 air?
  • What additional personal protective equipment (PPE) is required for hazardous compounding?
  • In which condition would a compounded sterile preparation be classified as high risk?
  • What are potential consequences of not adhering to guidelines regarding central line PN treatment duration?
  • What aspect of automated compounding devices increases their utility in sterile compounding?
  • What is the recommended temperature and pressure for steam sterilization using an autoclave?
  • What is one component of personnel training for high risk compounding?
  • Which sterilization method requires higher temperatures and longer duration than steam?
  • Why is documentation critical in the compounding process?
  • What is meant by "ISO class" in the context of cleanrooms?
  • What is the required temperature in a Containment Segregated Compounding Area (C-SCA)?
  • What is the significance of using a "closed system transfer device" (CSTD)?
  • Which of the following is NOT a source of exceeding CFU action levels in air sampling?
  • What type of air quality does a Clean Room (Buffer Room) need to achieve?
  • What is the primary goal of risk assessment in sterile compounding?
  • What is the maximum storage period for low-risk CSPs stored at controlled room temperature?
  • Why is it important to calculate the correct diluent volume when compounding a parenteral solution?
  • What is the classification of the air in a Compounding Aseptic Isolator (CAI)?
  • How should opened single-dose ampules be handled?
  • How is unidirectional air verified in the Primary Engineering Controls (PEC)?
  • In sterile compounding, how long is the depyrogenation process typically done at 250 degrees C?
  • What is necessary for the caulking around ceiling panels in a buffer room with inlaid panels?
  • What is a "master formulation record"?
  • Immediate remediation of Active (Viable) Air Sampling CFUs is required if which types of microbes are identified?
  • What is the incubation temperature for fungi growth using malt extract agar?
  • How often should wipe sampling be performed for hazardous drugs?
  • What is the required testing frequency for media fill in low-risk CSPs?
  • How often should personnel be re-evaluated for competency in sterile compounding?
  • What is the incubation temperature for media fill tests for high risk CSPs?
  • What is the main purpose of a Laminar Air Flow Workbench (LAFW)?
  • What type of compounded sterile products (CSPs) should never utilize bacteriostatic diluents?
  • What is a requirement regarding cleaning and disinfection in low-risk CSP preparation?
  • What are "the six rights" of medication administration?
  • Is it necessary to identify Active (Viable) Air Sampling CFUs?
  • Why is maintaining proper temperature control essential for compounded preparations?
  • What is a requirement for surfaces in the Sterile Product Complex (SPC)?
  • What is a necessary feature for all HD compounding areas?
  • What is one example of a medium risk compounded sterile preparation?
  • What should be the maximum temperature for a Sterile Product Complex?
  • What is the primary purpose of a compounding record in sterile compounding?
  • Which practice is essential for handling hazardous drugs?
  • What is the correct action when highly pathogenic microbes are identified in air sampling?
  • What can be a result of improper temperature control of compounded sterile preparations?
  • At what temperature should TSA be incubated for Active (Viable) Air Sampling?
  • What aspect of training is crucial for maintaining standard practices in sterile compounding?
  • What percentage of dextrose is typically recommended for central line parenteral nutrition due to phlebitis concerns?
  • What determines the exposure duration for critical sites to worse than ISO 5 air?
  • Why is it critical to verify drug compatibility during compounding?
  • In the context of compounded sterile preparations, why is it important to have documentation of the compounding procedure?
  • What should the environment be for compounding radiopharmaceuticals?
  • What is the primary condition under which immediate use compounding may be performed?
  • What defines critical sites in sterile compounding?
  • What are the key characteristics of storage shelving in a buffer room?
  • How can the risk of contamination at critical sites increase?
  • Which of the following is an appropriate method of sterility testing during compounding?
  • Carts in a buffer room should be constructed from which of the following materials?
  • What must junctions between ceilings and walls in the buffer room be designed to avoid?
  • Which biological indicator is used to verify steam sterilization effectiveness?
  • What characteristic should the exterior lens of lights in a buffer room have?
  • Which element is NOT part of the stability evaluation for compounded sterile preparations?
  • Which retention capacity requirement is crucial for filters during CSP sterilization?
  • What is the required pressure for the ISO 7 Negative Pressure Buffer Room?
  • What type of air filtration is not required in a Segregated Compounding Area (SCA)?
  • What is the preferred method for introducing HEPA filtered air into the SEC?
  • What type of training should staff receive regarding hazardous drugs?
  • When should the Sterile Compounding area (SPC) be certified?
  • How many entries into a sterile container are allowed for low-risk CSPs?
  • What factors influence the standards required for environmental conditions during CSP processing?
  • How should compounded sterile preparations be labeled for patient dispensing?
  • What is the volume needed for Active (Viable) Air Sampling according to USP 797?
  • What is the typical beyond-use date for a needle-punctured multiple-dose container?
  • What environment is required for preparing low-risk CSPs?
  • How should hazardous drugs be disposed of in a pharmacy?
  • What role does visual inspection serve in quality assurance for compounded preparations?
  • What method is commonly employed to verify the effectiveness of sterilization?
  • What is the function of a smoke study in a PEC?
  • What is one of the main areas prone to contamination during compounding activities?
  • Which types of items must be limited in a buffer room?
  • Describe the function of environmental monitoring in sterile compounding.
  • Which best describes the BUD for low-risk CSPs prepared in a segregated compounding area?
  • Which aspect directly relates to the patient's safety in sterile compounding?
  • What typical cycle is used for depyrogenation using dry heat?
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy